Drug Profile
Research programme: anti-inflammatories - Merck Serono
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Merck Serono
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Switzerland
- 31 Mar 2012 Preclinical trials in Inflammation in Switzerland (unspecified route)